Skip to main content

Xencor, Inc. (XNCR)

NASDAQ Stock Market Healthcare BiotechnologyView data quality →
40.4Fair

ValueMarkers Composite Index

Top 6%#42,225 of 44,714

DCF data not available

Piotroski
3/9
Weak
Beneish
-2.93
Low Risk
Altman
1.17
Distress
DCF Value
-
N/A
ROIC
-21.5%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Xencor, Inc. (XNCR) — VMCI valuation read

Headline read on XNCR: VMCI of 40/100 versus a Healthcare sector median of 50. The 10-point below-median position is what makes Xencor, Inc. a relative-value laggard in the mid-cap cohort, before any pillar-level review.

Form 4 filings on XNCR: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on XNCR: value (XNCR trades at 17.0x earnings, 6% below the Healthcare median of 18.0x), quality (ROIC of 11.0% sits 1.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of -1.7x leaves covenant headroom). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

XNCR rose 1.8% over the trailing 7 days, with a -16.7% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in XNCR’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.